Effectiveness of human adipose-derived stem cell therapy pretreated with hepatocyte growth factor in liver fibrosis mouse model

Ngoc Hong Vo, Trinh Van Le, Nam Hai Nguyen, Yen K.T. Nguyen, Thanh Minh Dang, Huy Quang Do, Nhung Hai Truong

Laboratory of Stem Cell Research and Application
Building B2-3, Linh Trung Campus, Thu Duc District, Ho Chi Minh 70000, Vietnam

Abstract

Background: Adipose-derived stem cells (ADSCs) have the potential therapeutic impact on the liver fibrosis. Hepatocyte growth factor (HGF) is pivotal for damage repair with its anti-apoptotic, anti-fibrotic and cell migration-promoting effect. In this study, the therapy with HGF-pretreated hADSCs was expected to enhance the therapeutic effect in the amelioration of liver fibrosis compared with untreated hADSCs.

Method: HGF-hADSCs were prepared by culturing hADSCs for seven days in the medium added HGF. HGF-hADSCs transplantation was performed to investigate the therapeutic effect of these cells on carbon tetrachloride (CCL4)-induced liver fibrosis in a mouse model.

Results: After seven days and fourteen days of cell transfusion, HGF-hADSCs ameliorated the liver fibrosis. The results showed the attenuation of the liver injury (ALT level), the down-regulation of procollagen-1 (7 days, 3-fold; 14 days, 6.7-fold) and alpha-smooth muscle actin (alpha-SMA) expression (7 days, 10-fold; 14 days, 2-fold), and the histological improvement. Notably, there was the significant difference in the procollagen-1 between HGF-hADSCs and untreated hADSCs groups. Thus, the therapy with HGF-hADSCs was more efficient in the liver fibrosis treatment compared with untreated hADSCs.

Conclusion: HGF pretreated hADSCs have a potential therapy in the treatment of liver fibrosis.

Keywords

Adipose-derived stem cell, hepatocyte growth factor, liver disease, liver cirrhosis, mesenchymal stem cell
Funding

This study was funded by Center of Science and Technology Development for Youth, Ho Chi Minh city

References